Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6

Inclusion Criteria: * Biopsy proven adenocarcinoma of gastric origin, primary or recurrent * Identification of Peritoneal seeding by CT or diagnostic laparoscopy * Patients confirmed to receive mFOLFOX6 on multidisciplinary outpatient clinic * No previous history of chemotherapy or 4week after the last chemotherapy for gastric cancer * Labs adequate for chemotherapy (within 2 weeks of enrollment) * Absolute Neutrophil Count: ≧ 1,500/mm³ * Hemoglobin level: ≧ 8.0g/dL * Platelet Count: ≧ 10×104/mm³ * AST (GOT), ALT (GPT): ≦ 100U/L * Total Bilirubin: ≦ 2.0mg/dL * Creatinine Clearance (CCl): ≧ 50mL/min * ECOG 0 - 2 * Her-2 negative on endoscopic biopsy * Age ≧ 20, \< 80 * Signed Informed consent form Exclusion Criteria: * Patients with other major medical disease or malignant tumors other than gastric cancer * Contraindication to 5-FU, Oxaliplatin, Leukovorin or Paclitaxel * Pregnant, breast-feeding women or with birth plan * Patients refusing treatment